150 related articles for article (PubMed ID: 18218275)
21. Nonischemic cardiomyopathy related to pegylated interferon and ribavirin.
Choy-Shan A; Berezovskaya S; Zinn A; Sedlis SP; Bini EJ
Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1438-40. PubMed ID: 19907230
[No Abstract] [Full Text] [Related]
22. [Pegylated intereferon hematological safety in comparison with standard].
Fazylov VKh; Manapova ÉR; Tkacheva SV; Sozinova IuM
Eksp Klin Gastroenterol; 2012; (6):96-9. PubMed ID: 23402198
[TBL] [Abstract][Full Text] [Related]
23. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
Such Díaz A; Barrueco N; Esteban Alba C; Escobar Rodríguez I
Farm Hosp; 2011; 35(2):93-4. PubMed ID: 20615736
[No Abstract] [Full Text] [Related]
24. A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C.
Goto T; Ohshima S; Miura K; Shibuya T; Sato W; Dohmen T; Kamada K; Kanata R; Sakai T; Chiba M; Sugimoto Y; Minami S; Ohnishi H
Intern Med; 2013; 52(18):2057-60. PubMed ID: 24042512
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
Rogers CJ; Romagosa R; Vincek V
J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
[No Abstract] [Full Text] [Related]
26. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK
Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182
[No Abstract] [Full Text] [Related]
27. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization.
Foruny JR; Blázquez J; Moreno A; Bárcena R; Gil-Grande L; Quereda C; Pérez-Elías MJ; Moreno J; Sánchez J; Muriel A; Rodriguez-Sagrado MA; Moreno S
Eur J Gastroenterol Hepatol; 2005 Nov; 17(11):1157-64. PubMed ID: 16215426
[TBL] [Abstract][Full Text] [Related]
28. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
Klimacka-Nawrot E; Musialik J; Suchecka W; Petelenz M; Hartman M; Lichtański P; Błońska-Fajfrowska B
Wiad Lek; 2010; 63(4):289-99. PubMed ID: 21608370
[TBL] [Abstract][Full Text] [Related]
29. [Sarcoïdose in patient with chronic hepatitis C treated with pegylated interferon].
Moudden MK; Ziadi T; Al Bouzidi A; Ouarssani A; Hadri L; El Baaj M
Rev Pneumol Clin; 2014 Dec; 70(6):362-5. PubMed ID: 25131364
[TBL] [Abstract][Full Text] [Related]
30. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
Halász T; Farkas A; Tolvaj G; Horváth G
Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
[TBL] [Abstract][Full Text] [Related]
31. Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil.
Mendes-Corrêa MC; Bittar RS; Salmito N; Oiticica J
Braz J Infect Dis; 2011; 15(1):87-9. PubMed ID: 21412597
[TBL] [Abstract][Full Text] [Related]
32. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
Verma P; Dayal S; Jain VK; Amrani A
J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937
[TBL] [Abstract][Full Text] [Related]
33. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
Enjoji M; Dainichi T; Gondo H; Urabe K
Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
[TBL] [Abstract][Full Text] [Related]
34. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
[TBL] [Abstract][Full Text] [Related]
35. Branch retinal artery occlusion and central retinal vein occlusion associated with pegylated interferon plus ribavirin combination therapy for chronic hepatitis C.
Watanabe M; Ogasawara S; Takahashi A; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Shibuya A; Koizumi W
Cutan Ocul Toxicol; 2012 Sep; 31(3):253-7. PubMed ID: 22172047
[TBL] [Abstract][Full Text] [Related]
36. Association between virological response and decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in HCV genotype 1: another story.
Dai CY; Huang CF; Huang JF; Chuang WL; Yu ML
Hepatology; 2011 May; 53(5):1774-5; author reply 1775-6. PubMed ID: 21520186
[No Abstract] [Full Text] [Related]
37. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
Slim J; Afridi MS
Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
[TBL] [Abstract][Full Text] [Related]
38. Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.
Sagir A; Wettstein M; Heintges T; Häussinger D
Dig Dis Sci; 2002 Mar; 47(3):562-3. PubMed ID: 11911342
[No Abstract] [Full Text] [Related]
39. Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C.
Balderramo DC; García O; Colmenero J; Espinosa G; Forns X; Ginès P
Dig Liver Dis; 2009 Jul; 41(7):e4-7. PubMed ID: 18243078
[TBL] [Abstract][Full Text] [Related]
40. Severe allergic eczema due to pegylated alpha-interferon may abate after switching to daily conventional alpha-interferon.
Veldt BJ; Schalm SW; Janssen HL
J Clin Gastroenterol; 2007 Apr; 41(4):432. PubMed ID: 17413616
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
